Jeffrey Schlom, PhD-
Chief of Laboratory of Tumor Immunology and Biology at NCI. Principal Investigator on awarded Syntrix-NCI CRADA to fund SX-682 through Phase II.0
Elizabeth Mittendorf, MD, PhD-
Surgical oncologist focused on breast cancer immunotherapy. Principal Investigator and key design lead of SX-682 Phase I/II breast cancer trial.
Rami Komrokji, MD-
Professor and head of the Leukemia and MDS Section at the Moffitt Cancer Center. Principal Investigator of SX-682 MDS Phase I/II trial.
McGarry Houghton, MD-
Expert on tumor microenvironment and host immune response in lung cancer.
Dimitry Gabrilovitch, MD, PhD-
Leads Wistar’s Translational Tumor Immunology Program. MDSC pioneer and co-investigator in SX-682 melanoma trial.
Keith Flaherty, MD-
IO thought leader in melanoma. PI of SX-682 Phase I/II melanoma trial.
Ronald DePinho, MD-
Partner laboratory on SX-682 prostate cancer Nature paper. Former President of MD Anderson Cancer Center.
Martin “Mac” Cheever, MD-
Principal Investigator of the National Cancer Institute-funded Cancer Immunotherapy Trials Network.
Posts tagged with ‘collaborators’
Syntrix Pharmaceuticals > Team > collaborators